Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
P/E ratio for Puma Biotechnology, Inc. (PBYI)
P/E ratio as of 2023: 9.45
According to Puma Biotechnology, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 9.45. At the end of 2022 the company had a P/E ratio of 207.21.
P/E ratio history for Puma Biotechnology, Inc. from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 9.45 |
| 2022 | 207.21 |
| 2021 | -4.25 |
| 2020 | -6.77 |
| 2019 | -4.10 |
| 2018 | -6.80 |
| 2017 | -12.58 |
| 2016 | -3.70 |
| 2015 | -10.53 |
| 2014 | -40.00 |
| 2013 | -54.35 |
| 2012 | -5.48 |
| 2011 | -27.42 |
| 2010 | -6788.40 |
| 2009 | -2494.65 |
| 2008 | -2982.32 |
| 2007 | -36.45 |